Supplemental Tables
Supplemental Table 1 . Cytoreductive treatment regiments. During the course of disease, 36 patients (31%) received a cytoreductive treatment with a median of 2 different regiments (range 1 -5). TKI; tyrosine kinase inhibitor; HSCT, hematopoietic stem cell transplantation. Table 2 . Characteristics of control patients. FFPE bone marrow sections from lymphoma patients undergoing a staging biopsy, and in whom no BM infiltration was detected, were used as control material for the assessment of the clinical specificity of KIT D816V testing. Supplemental Table 4 . Assessment of mast cells by flow cytometry in a subset of systemic mastocytosis (SM) patients. Mast cell (MC) infiltration (%) determined by flow cytometry and histology, KIT D816V variant allele frequency (VAF) derived from tissue and liquid specimen, and aberrant surface expression of CD2 and CD25 on MC in 43 samples of 37 patients with SM. ISM, indolent SM; ASM, aggressive SM; MCL, mast cell leukemia; SM-AHN, SM with an associated hematological neoplasm; n.t., not tested; *KIT D816H positive patient.
Supplemental
Supplemental Table 5 . Turnaround-time for molecular analyses of KIT D816V. Turnaround-time (TAT) for molecular analyses (qualitative PCR, KIT D816V mutation analysis using melting curve analysis after PNA-mediated PCR clamping; digital PCR) of batches of 8 samples is shown in minutes (min). Hands-on time as part of the total TAT is display separately. (DIN; B) , or sample age (C). Samples with a copy number <100 were excluded from further before analysis (n=11, red zone). Samples with a total number of KIT copies from 100 to 1000 were considered to have a limited sensitivity (n=35, grey zone). (D) KIT D816V VAF and assay sensitivity in diagnostic FFPE BM section of KIT D816V-positive ISM patients (n=91). Samples tested negative by melting curve analysis after PNA-mediated PCR clamping are depicted in red.
Supplemental Methods

Quantification of bone marrow mast cell infiltration
Formalin-fixed, paraffin-embedded (FFPE) bone marrow (BM) sections were stained with hematoxylin and eosin (H&E), Giemsa and Napthtol-AS-D-chloracetate-esterase stainings according to standard techniques, and immunohistochemistry with antibodies against tryptase, CD117 and CD25 was performed as described. Table 4 .
Serum tryptase measurement
Total tryptase levels in serum were determined by a commercial fluoroenzymeimmunoassay (ImmunoCAP, Thermo Fisher Scientific, Uppsala, Sweden) on a Phadia 250 platform (Thermo Fisher Scientific) according to the recommendations of the manufacturer. The lower limit of detection amounted to 1 ng/ml.
5
DNA extraction
Genomic DNA (gDNA) was extracted from FFPE BM sections using the EZ1 DNA Tissue Kit and the EZ1 Advanced XL Instrument (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. 20 BM sections à 10µm were isolated per sample and further subjected to dPCR analysis. DNA extraction of PB and BM was performed using the QIAsymphony Sp Instrument with the QIAsymphony DNA Midi Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations.
DNA from FFPE BM sections was quantified using the Qubit 3.0 fluorometer and the Qubit dsDNA HS assay kit (Thermo Fisher Scientific), and DNA Integrity Number (DIN) was assessed using the Agilent 2200 TapeStation system and the genomic DNA ScreenTape assay (Agilent Technologies, Santa Clara, CA).
Digital PCR for KIT D816V
dPCR was performed with the PrimePCR™ ddPCR mutation assay for KIT wild-type and the KIT D816V point mutation (Bio-Rad Laboratories GmbH, Munich, Germany)
as described. 6 The wild-type and D816V alleles were labelled with FAM-and HEXfluorochromes respectively. Reaction volume was 22 µL, consisting of 11 µL ddPCR supermix for probes (Bio-Rad Laboratories), 1.1 µL of each primer/probe mix, 1.1 µL of HindIII restriction enzyme (20 units/µl; New England Biolabs, Ipswich, UK) and 7.7 µL genomic DNA (with a maximal concentration of 40 ng/µl). gDNA extracted from PB and/or aspirated BM cells was diluted to 40 ng/µl. gDNA isolated from FFPE BM sections was applied without dilution at a total volume of 7.7 µl. Automated droplet generator (Bio-Rad Laboratories) was used to partition the reaction mix into droplets followed by PCR reaction (95°C for 10 min, followed by 40 cycles of 94°C for 30 s, 55°C for 1 min, and one final cycle of 98°C for 10 min). Cycled droplets were read on the QX-200 droplet-reader (Bio-Rad Laboratories) and analysis of the ddPCR data was performed using the QuantaSoft analysis software v1.7.4.0917 (Bio-Rad Laboratories).
The threshold between the positive and negative droplet clusters was set for both fluorescence channels based on control samples. 6 The KIT D816V variant allele fraction (VAF) was calculated by dividing the number of mutated KIT D816V copies by the total number of KIT copies, and results were expressed as percent mutant alleles.
FFPE samples with a total number of KIT copies <100 were considered to have failed dPCR and were excluded from further analysis (n=11). Samples with a total number of KIT copies from 100 to 1000 were considered to have a limited sensitivity (n=35). The KIT copy number was found to correlate directly to the DNA concentration and DIN and inversely to the age of the FFPE block (Supplemental Figure 3A -C).
Sample processing from BM puncture, fixation, decalcification, embedding and DNA isolation of FFPE BM samples in a prospective setting is possible within 4 working days. However, processing of native BM biopsy material can be performed much faster within 24 hours. Assay turnaround time (TAT) and hands-on time of qualitative PCR or dPCR depends on the amount of samples used in the assay. TAT and hands-on time for 8 samples are depicted in Supplemental Table 5 . Whereas, there is no major differences in hands-on time between melting curve analysis after peptide nucleic acid-mediated PCR clamping and dPCR, total assay time of dPCR is slightly longer. When analyzing a larger amount of samples by dPCR, the total assay time is increased by approximately 2 minutes per sample due to the sequential acquisition of samples in the droplet-reader with no relevant effect on hands-on time.
Statistical analysis
Statistical analysis was performed using R (version 3.4.2, Vienna, Austria) 7 and
GraphPad Prism (GraphPad Software, La Jolla, CA). Categorical data was assessed by
McNemar's Chi-square test. Metric data is given as median and group differences were evaluated by the Mann-Whitney-U test. The correlation was assessed by applying Spearman's rank correlation coefficient (r). Differences between the dPCR results obtained from different specimen were graphically displayed using the Bland-Altman plot and statistically compared by applying Passing-Bablok regression. 8 The adjusted prognostic significance of KIT D816V tissue mutation burden with regard to overall survival (OS) and progression free survival (PFS) was analyzed by Cox proportional hazard regression. Optimal cut-off values were calculated by applying the maximally selected rank statistics method. 9 Kaplan-Meier survival plots were used for graphical representation, and difference between survivals curves were analyzed using the logrank test. Differences were considered to be significant when the p-value was <0.05.
